JP2011528656A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528656A5
JP2011528656A5 JP2011518816A JP2011518816A JP2011528656A5 JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5 JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5
Authority
JP
Japan
Prior art keywords
drug delivery
delivery system
administered
eye
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528656A (ja
Filing date
Publication date
Priority claimed from US12/176,238 external-priority patent/US8821870B2/en
Application filed filed Critical
Publication of JP2011528656A publication Critical patent/JP2011528656A/ja
Publication of JP2011528656A5 publication Critical patent/JP2011528656A5/ja
Pending legal-status Critical Current

Links

JP2011518816A 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法 Pending JP2011528656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/176,238 US8821870B2 (en) 2008-07-18 2008-07-18 Method for treating atrophic age related macular degeneration
US12/176,238 2008-07-18
PCT/US2009/050373 WO2010009034A2 (en) 2008-07-18 2009-07-13 Method for treating atrophic age related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014169846A Division JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法

Publications (2)

Publication Number Publication Date
JP2011528656A JP2011528656A (ja) 2011-11-24
JP2011528656A5 true JP2011528656A5 (enExample) 2012-08-16

Family

ID=41530477

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011518816A Pending JP2011528656A (ja) 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Country Status (11)

Country Link
US (3) US8821870B2 (enExample)
EP (4) EP2307055B1 (enExample)
JP (3) JP2011528656A (enExample)
KR (1) KR20110047196A (enExample)
CN (2) CN107412778A (enExample)
AU (1) AU2009271168B2 (enExample)
BR (1) BRPI0915981A2 (enExample)
CA (1) CA2731270C (enExample)
ES (3) ES2897560T3 (enExample)
RU (3) RU2668371C2 (enExample)
WO (1) WO2010009034A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2482804A1 (en) * 2009-10-01 2012-08-08 Evonik Degussa Corporation Microparticle compositions and methods for treating age-related macular degeneration
JP5212849B2 (ja) * 2010-01-14 2013-06-19 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US20130210876A1 (en) * 2010-01-21 2013-08-15 Allergan, Inc Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
CN102770135A (zh) * 2010-01-21 2012-11-07 阿勒根公司 眼内压降低作用持续时间长的α-2肾上腺素能激动剂
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
EP2640360A2 (en) * 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
WO2012149278A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Sustained release latanoprost implant
RS60051B1 (sr) * 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
US9592251B2 (en) 2011-06-16 2017-03-14 The Hong Kong University Of Science And Technology Multi-vinylsulfone containing molecule
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
CN105749282A (zh) * 2011-07-19 2016-07-13 威尔弗雷德·杰弗里斯 阿尔茨海默氏病的诊断和治疗方法
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US20130156766A1 (en) * 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
TWI663985B (zh) * 2012-09-27 2019-07-01 美商歐樂根公司 用於持續釋放蛋白質之可生物降解的藥物傳遞系統
CA3240136A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN104884133B (zh) 2013-03-14 2018-02-23 艾肯运动与健康公司 具有飞轮的力量训练设备
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
US20160166701A1 (en) * 2013-07-05 2016-06-16 Therakine Biodelivery Gmbh Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
EP3071181B1 (en) * 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
EP3623020B1 (en) 2013-12-26 2024-05-01 iFIT Inc. Magnetic resistance mechanism in a cable machine
CN106470739B (zh) 2014-06-09 2019-06-21 爱康保健健身有限公司 并入跑步机的缆索系统
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US20180116975A1 (en) * 2015-02-26 2018-05-03 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP6836512B2 (ja) 2015-03-31 2021-03-03 イルドン ファーム カンパニー リミテッド 組織透過性ペプチドと抗血管内皮細胞成長因子製剤が融合された融合タンパク質を有効成分として含む眼疾患の予防及び治療用薬学的組成物
JP6887377B2 (ja) 2015-05-29 2021-06-16 生化学工業株式会社 グリコサミノグリカン誘導体とケモカイン受容体活性調節材とを含む組成物
US10953305B2 (en) 2015-08-26 2021-03-23 Icon Health & Fitness, Inc. Strength exercise mechanisms
US10940360B2 (en) 2015-08-26 2021-03-09 Icon Health & Fitness, Inc. Strength exercise mechanisms
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
KR102725051B1 (ko) 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2017217397B2 (en) * 2016-02-08 2019-10-10 The Johns Hopkins University Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
WO2017148904A1 (en) * 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
US10293211B2 (en) 2016-03-18 2019-05-21 Icon Health & Fitness, Inc. Coordinated weight selection
US10441840B2 (en) 2016-03-18 2019-10-15 Icon Health & Fitness, Inc. Collapsible strength exercise machine
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10252109B2 (en) 2016-05-13 2019-04-09 Icon Health & Fitness, Inc. Weight platform treadmill
EP3463349B1 (en) * 2016-05-25 2021-08-04 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
US10661114B2 (en) 2016-11-01 2020-05-26 Icon Health & Fitness, Inc. Body weight lift mechanism on treadmill
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
CA3097123A1 (en) * 2018-04-17 2019-10-24 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab for use of treating diseases
KR102192768B1 (ko) * 2018-12-07 2020-12-18 전북대학교산학협력단 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물
DE102019112917B4 (de) * 2019-05-16 2021-07-22 Carl Zeiss Meditec Ag Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
WO2020264438A2 (en) 2019-06-27 2020-12-30 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
CA3144406A1 (en) 2019-06-27 2020-12-30 Layerbio, Inc. Ocular device delivery methods and systems
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
FI3884929T3 (fi) 2020-03-25 2023-08-07 Ocular Therapeutix Inc Tyrosiinikinaasi-inhibiittoria sisältävä silmäimplantti
EP4171544A4 (en) * 2020-06-26 2024-07-24 Purdue Research Foundation PHARMACEUTICAL FORMULATIONS OF GRISEOFULVINE FOR LONG-TERM EYE ADMINISTRATION
WO2022155242A1 (en) * 2021-01-12 2022-07-21 The Regents Of The University Of Michigan Treatment and prevention of dry macular degeneration
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2446405A (en) 1945-10-31 1948-08-03 Hazeltine Research Inc Tunable ultra high frequency resonator system
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) * 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
CA2361615A1 (en) * 1999-02-08 2000-08-10 Human Genome Sciences, Inc. The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US20040229960A1 (en) 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
PL223153B1 (pl) * 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7589057B2 (en) * 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
GB2438544A (en) * 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
DK1933871T3 (da) * 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP1959925B1 (en) * 2005-12-02 2016-11-23 (OSI) Eyetech, Inc. Controlled release microparticles
WO2007073489A2 (en) * 2005-12-22 2007-06-28 Trustees Of Boston University Molecules for gene delivery and gene therapy, and methods of use thereof
WO2007089673A2 (en) * 2006-01-26 2007-08-09 Acucela, Inc. Compositions and methods for treatment of ophthalmic diseases and disorders
EP2012826B1 (en) 2006-05-04 2016-04-13 Fovea Pharmaceuticals Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
MX2009002054A (es) * 2006-08-31 2009-05-01 Abraxis Bioscience Llc Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
BRPI0719379A2 (pt) * 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2968112C (en) 2016-05-26 2025-09-23 Op Hygiene Ip Gmbh Dispenser servicing in a multiple washroom facility
US11210687B2 (en) 2019-05-23 2021-12-28 Capital One Services, Llc Intelligent preprocessing routing to decisioning services

Similar Documents

Publication Publication Date Title
JP2011528656A5 (enExample)
JP6700348B2 (ja) 持続型薬物送達インプラント
RU2018133133A (ru) Способ лечения атрофической возрастной макулярной дегенерации
JP2008540552A5 (enExample)
US20240082150A1 (en) Ocular compositions
JP2018500394A5 (enExample)
AU2010298480B2 (en) Injectable aqueous ophthalmic composition and method of use therefor
JP6882186B2 (ja) スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
Goyal et al. Current nanotechnological strategies for treating glaucoma
JP2007535552A5 (enExample)
JP2017537985A5 (enExample)
JP2009535422A5 (enExample)
JP2012521997A5 (enExample)
JP2013526572A5 (enExample)
JP2007535564A5 (enExample)
CN103990185B (zh) 一种卡拉胶和明胶微球栓塞剂及其制备方法
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
JP2013523748A5 (enExample)
Mittal et al. Recent advancemnts in biodegradable ocular implants
WO2005018608A1 (ja) 微粒子テノン嚢下投与ドラッグデリバリーシステム
CA3124280A1 (en) Ocular compositions
JP2005132737A (ja) 埋込型製剤の薬物保持担体
RU2021117158A (ru) Улучшенные агрегированные микрочастицы